TY - JOUR
T1 - Pharmacogenomics in clinical care
AU - Wysocki, Kenneth
AU - Seibert, Diane
N1 - Publisher Copyright:
© 2019 American Association of Nurse Practitioners.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Health care designed specifically for a person based on their genetic makeup ("personalized" or "precision" medicine) is expanding rapidly, especially in the area of drug selection. Pharmacogenomic (PGx) testing, when drugs and doses are selected based on an individual's genetic profile, is increasingly being used to guide the selection of drugs or therapies to optimize outcomes and minimize side effects. Based on an individual's genetic blueprint, health care providers now have important information about how a drug is likely to behave in that individual's body. Pharmacogenomic information on drug labels is now available for nearly 250 drugs. Health care organizations are also increasingly making this information available to customers to reduce emergency department visits, improve outcomes (selecting the right chemotherapy doses), and reduce cost. This study reviews some of the challenges and benefits on using PGx testing to improve clinical outcomes.
AB - Health care designed specifically for a person based on their genetic makeup ("personalized" or "precision" medicine) is expanding rapidly, especially in the area of drug selection. Pharmacogenomic (PGx) testing, when drugs and doses are selected based on an individual's genetic profile, is increasingly being used to guide the selection of drugs or therapies to optimize outcomes and minimize side effects. Based on an individual's genetic blueprint, health care providers now have important information about how a drug is likely to behave in that individual's body. Pharmacogenomic information on drug labels is now available for nearly 250 drugs. Health care organizations are also increasingly making this information available to customers to reduce emergency department visits, improve outcomes (selecting the right chemotherapy doses), and reduce cost. This study reviews some of the challenges and benefits on using PGx testing to improve clinical outcomes.
KW - Cytochrome P450
KW - personalized medicine
KW - PGx
KW - pharmacogenomics
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85071349649&partnerID=8YFLogxK
U2 - 10.1097/JXX.0000000000000254
DO - 10.1097/JXX.0000000000000254
M3 - Article
C2 - 31348145
AN - SCOPUS:85071349649
SN - 2327-6924
VL - 31
SP - 443
EP - 446
JO - Journal of the American Association of Nurse Practitioners
JF - Journal of the American Association of Nurse Practitioners
IS - 8
ER -